• 1
    Dhodapkar, M. V., Dhodapkar, K. M. and Palucka, A. K., Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Differ. 2008. 15: 3950.
  • 2
    Piersma, S. J., Welters, M. J. and van der Burg, S. H., Tumor-specific regulatory T cells in cancer patients. Hum. Immunol. 2008. 69: 241249.
  • 3
    Munn, D. H. and Mellor, A. L., The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 2006. 213: 146158.
  • 4
    Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005. 5: 263274.
  • 5
    Zitvogel, L., Apetoh, L., Ghiringhelli, F. and Kroemer, G., Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008. 8: 5973.
  • 6
    McDonnell, A. M., Robinson, B. W. and Currie, A. J., Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin. Dev. Immunol. 2010. 2010: 539519.
  • 7
    Iero, M., Valenti, R., Huber, V., Filipazzi, P., Parmiani, G., Fais, S. and Rivoltini, L., Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008. 15: 8088.
  • 8
    Gregory, C. D. and Pound, J. D., Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J. Pathol. 2010. 223: 177194.
  • 9
    Albert, M. L., Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat. Rev. Immunol. 2004. 4: 223231.
  • 10
    Zitvogel, L., Kepp, O. and Kroemer, G., Decoding cell death signals in inflammation and immunity. Cell 2010. 140: 798804.
  • 11
    Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A. et al., Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 2003. 170: 49054913.
  • 12
    Morelli, A. E. and Thomson, A. W., Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol. 2007. 7: 610621.
  • 13
    Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A. C., Chapman, D. C., Durchschlag, M. et al., Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009. 28: 578590.
  • 14
    van der Most, R. G., Currie, A. J., Robinson, B. W. and Lake, R. A., Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 2008. 15: 1320.
  • 15
    Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Hopner, S. et al., Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007. 110: 12251232.
  • 16
    Battaglia, A., Buzzonetti, A., Baranello, C., Ferrandina, G., Martinelli, E., Fanfani, F., Scambia, G. et al., Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol. Immunother. 2009. 58: 13631373.
  • 17
    Weigert, A., Cremer, S., Schmidt, M. V., von Knethen, A., Angioni, C., Geisslinger, G. and Brune, B., Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood 2010. 115: 35313540.
  • 18
    Wetter, J. A., Revankar, C. and Hanson, B. J., Utilization of the Tango beta-arrestin recruitment technology for cell-based EDG receptor assay development and interrogation. J. Biomol. Screen 2009. 14: 11341141.
  • 19
    Guerrero, M., Urbano, M., Zhao, J., Crisp, M., Chase, P., Hodder, P., Schaeffer, M. T. et al., Discovery, design and synthesis of novel potent and selective sphingosine-1-phosphate 4 receptor (S1P-R) agonists. Bioorg. Med. Chem. Lett. 2011. 22: 537542.
  • 20
    Williams, C. A., Harry, R. A. and McLeod, J. D., Apoptotic cells induce dendritic cell-mediated suppression via interferon-gamma-induced IDO. Immunology 2008. 124: 89101.
  • 21
    Gee, K., Guzzo, C., Che Mat, N. F., Ma, W. and Kumar, A., The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm. Allergy Drug Targets 2009. 8: 4052.
  • 22
    Shevach, E. M., Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009. 30: 636645.
  • 23
    Linnemann, C., Schildberg, F. A., Schurich, A., Diehl, L., Hegenbarth, S. I., Endl, E., Lacher, S. et al., Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology 2009. 128: e728e737.
  • 24
    Mandapathil, M., Szczepanski, M. J., Szajnik, M., Ren, J., Lenzner, D. E., Jackson, E. K., Gorelik, E. et al., Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin. Cancer Res. 2009. 15: 63486357.
  • 25
    Eltzschig, H. K., Thompson, L. F., Karhausen, J., Cotta, R. J., Ibla, J. C., Robson, S. C. and Colgan, S. P., Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 2004. 104: 39863992.
  • 26
    Zeelenberg, I. S., van Maren, W. W., Boissonnas, A., Van Hout-Kuijer, M. A., Den Brok, M. H., Wagenaars, J. A., van der Schaaf, A. et al., Antigen localization controls T cell-mediated tumor immunity. J. Immunol. 2011. 187: 12811288.
  • 27
    Rivera, J., Proia, R. L. and Olivera, A., The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 2008. 8: 753763.
  • 28
    Larousserie, F., Bardel, E., Pflanz, S., Arnulf, B., Lome-Maldonado, C., Hermine, O., Bregeaud, L. et al., Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am. J. Pathol. 2005. 166: 12171228.
  • 29
    Yoshida, H., Nakaya, M. and Miyazaki, Y., Interleukin 27: a double-edged sword for offense and defense. J. Leukoc. Biol. 2009. 86: 12951303.
  • 30
    Kamiya, S., Owaki, T., Morishima, N., Fukai, F., Mizuguchi, J. and Yoshimoto, T., An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+T cells. J. Immunol. 2004. 173: 38713877.
  • 31
    Schneider, R., Yaneva, T., Beauseigle, D., El-Khoury, L. and Arbour, N., IL-27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur. J. Immunol. 2011. 41: 4759.
  • 32
    Murugaiyan, G., Mittal, A., Lopez-Diego, R., Maier, L. M., Anderson, D. E. and Weiner, H. L., IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+T cells. J. Immunol. 2009. 183: 24352443.
  • 33
    Schenk, U., Westendorf, A. M., Radaelli, E., Casati, A., Ferro, M., Fumagalli, M., Verderio, C. et al., Purinergic control of T-cell activation by ATP released through pannexin-1 hemichannels. Sci. Signal. 2008. 1: ra6.
  • 34
    Hausler, S. F., Montalban del Barrio, I., Strohschein, J., Anoop Chandran, P., Engel, J. B., Honig, A., Ossadnik, M. et al., Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T-cell function and NK cell cytotoxicity. Cancer Immunol. Immunother. 2011. 60: 14051418.
  • 35
    Sancho, D., Gomez, M. and Sanchez-Madrid, F., CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005. 26: 136140.
  • 36
    Chen, M. L., Pittet, M. J., Gorelik, L., Flavell, R. A., Weissleder, R., von Boehmer, H. and Khazaie, K., Regulatory T cells suppress tumor-specific CD8 T-cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA 2005. 102: 419424.
  • 37
    Vogler, I. and Steinle, A., Vis-a-vis in the NKC: genetically linked natural killer cell receptor/ligand pairs in the natural killer gene complex (NKC). J. Innate Immun. 3: 227235.
  • 38
    Zitvogel, L., Kepp, O. and Kroemer, G., Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 2011. 8: 151160.
  • 39
    Le, D. T., Pardoll, D. M. and Jaffee, E. M., Cellular vaccine approaches. Cancer J. 2010. 16: 304310.
  • 40
    Exley, M. A., Wilson, B. and Balk, S. P., Isolation and functional use of human NKT cells. Curr. Protoc. Immunol. 2010. 90:
  • 41
    Qian, F., Villella, J., Wallace, P. K., Mhawech-Fauceglia, P., Tario, J. D., Jr., Andrews, C., Matsuzaki, J. et al., Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 2009. 69: 54985504.
  • 42
    Herr, B., Zhou, J., Werno, C., Menrad, H., Namgaladze, D., Weigert, A., Dehne, N. et al., The supernatant of apoptotic cells causes transcriptional activation of hypoxia-inducible factor-1alpha in macrophages via sphingosine-1-phosphate and transforming growth factor-beta. Blood 2009. 114: 21402148.
  • 43
    Zimmermann, S. Y., Esser, R., Rohrbach, E., Klingebiel, T. and Koehl, U., A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20% of normal cells. J. Immunol. Methods 2005. 296: 6376.
  • 44
    Campanelli, R., Palermo, B., Garbelli, S., Mantovani, S., Lucchi, P., Necker, A., Lantelme, E. et al., Human CD8 co-receptor is strictly involved in MHC-peptide tetramer-TCR binding and T-cell activation. Int. Immunol. 2002. 14: 3944.